- Home
- SFWL vs PLRX Comparison
SFWL vs PLRX Comparison
Compare SFWL & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFWL
- PLRX
- Stock Information
- Founded
- SFWL 2001
- PLRX 2015
- Country
- SFWL China
- PLRX United States
- Employees
- SFWL N/A
- PLRX N/A
- Industry
- SFWL Trucking Freight/Courier Services
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- SFWL Industrials
- PLRX Health Care
- Exchange
- SFWL Nasdaq
- PLRX Nasdaq
- Market Cap
- SFWL 82.5M
- PLRX 93.3M
- IPO Year
- SFWL 2023
- PLRX 2020
- Fundamental
- Price
- SFWL $1.02
- PLRX $1.79
- Analyst Decision
- SFWL
- PLRX Hold
- Analyst Count
- SFWL 0
- PLRX 11
- Target Price
- SFWL N/A
- PLRX $3.79
- AVG Volume (30 Days)
- SFWL 8.3K
- PLRX 976.6K
- Earning Date
- SFWL 08-27-2025
- PLRX 11-06-2025
- Dividend Yield
- SFWL N/A
- PLRX N/A
- EPS Growth
- SFWL 31.68
- PLRX N/A
- EPS
- SFWL 0.14
- PLRX N/A
- Revenue
- SFWL $540,461,000.00
- PLRX N/A
- Revenue This Year
- SFWL N/A
- PLRX N/A
- Revenue Next Year
- SFWL N/A
- PLRX N/A
- P/E Ratio
- SFWL $6.98
- PLRX N/A
- Revenue Growth
- SFWL 21.10
- PLRX N/A
- 52 Week Low
- SFWL $0.84
- PLRX $1.10
- 52 Week High
- SFWL $1.36
- PLRX $15.80
- Technical
- Relative Strength Index (RSI)
- SFWL 53.26
- PLRX 59.50
- Support Level
- SFWL $0.91
- PLRX $1.45
- Resistance Level
- SFWL $1.03
- PLRX $1.72
- Average True Range (ATR)
- SFWL 0.05
- PLRX 0.12
- MACD
- SFWL 0.01
- PLRX -0.00
- Stochastic Oscillator
- SFWL 84.44
- PLRX 67.00
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.